La chaîne d'options affiche les données clés des options sur actions de Shineco à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Shineco..

Shineco (NASDAQ:SISI) Stock, Chaîne d'Options

Shineco

Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.

Shineco Inc

Goldman Sachs analyst James Schneider initiates coverage on SanDisk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) with a Buy rating and announces Price Target of $55.

News

Price Target

Initiation

Analyst Ratings

SNDK

Goldman Sachs Initiates Coverage On SanDisk with Buy Rating, Announces Price Target of $55

WIIM

MREO

Mereo BioPharma Group shares are trading lower after Needham cut its price target on the stock from $7 to $5.

Goldman Sachs analyst Toshiya Hari initiates coverage on Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy rating and announces Price Target of $170.

Goldman Sachs Initiates Coverage On Seagate Tech Hldgs with Buy Rating, Announces Price Target of $170

ConAgra Brands shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY26 adjusted EPS guidance below estimates.

Goldman Sachs analyst Toshiya Hari initiates coverage on Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Buy rating and announces Price Target of $115.

LRCX

Goldman Sachs Initiates Coverage On Lam Research with Buy Rating, Announces Price Target of $115

SMPL

Simply Good Foods shares are trading lower after the company reported worse-than-expected Q3 sales results and issued FY25 sales guidance below estimates.

Goldman Sachs analyst Christine Cho downgrades Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) from Buy to Neutral and raises the price target from $66 to $67.

Downgrades

CAKE

Goldman Sachs Downgrades Cheesecake Factory to Neutral, Raises Price Target to $67

MP Materials shares are trading higher after the company announced it has entered into a public-private partnership with the U.S. Department ot Defense consisting of a multi-billion dollar package of investments and long-term commitments.

Benchmark analyst Mark Zgutowicz maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $700 to $840.

SPOT

Benchmark Maintains Buy on Spotify Technology, Raises Price Target to $840

Strengthening American cybersecurity resilience within the defense manufacturing base and beyond
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2F___https%3A%2Fwww.boozallen.com%2Fmenu%2Fmedia-center%2Fq1-2023%2Fbooz-allen-maintains-cmmi-maturity-level-5-ratings.html___.YzJ1OnBhdWxiYWtlcm5vdGlmaWVkY29tOmM6bzo4NTNmODUzN2IwMzZiMjYwODZkNGE2YjcyNjI4ZDBmNjo2OmNhYWI6M2ZhYmRhZjEzOTRmYWQzN2E3NTQ5MTYwMDNlYzdlMzBmM2JiY2ExMDFjYjVjMGI4NzJmNDhkNTc3Yjg2MDA5MzpwOlQ6Tg&amp;esheet=54288050&amp;newsitemid=20250710316124&amp;lan=en-US&amp;anchor=Booz+Allen+Hamilton&amp;index=1&amp;md5=ea30b2d91301dd63f045a5284af5a85c">Booz Allen Hamilton</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) today announced that its corporate venture capital arm, Booz Allen Ventures, has made a strategic investment in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcorsha.com%2F&amp;esheet=54288050&amp;newsitemid=20250710316124&amp;lan=en-US&amp;anchor=Corsha&amp;index=2&amp;md5=5b0e971e7a03d322881eed8312b2a11c">Corsha</a>, the first and only Machine Identity Provider (mIDP) built to secure communication across operational systems and critical infrastructure. This investment will accelerate the use of advanced technology solutions to reinforce U.S. defenses against increasingly sophisticated and frequent cyberattacks.
Operating in demanding environments and working with key partners such as the U.S. Air Force, Corsha uses multi-factor authentication to secure machine-to-machine communication and proactively defend against emerging cyber threats. Corsha leverages advanced behavioral analytics to detect unusual patterns and spot potential threats, blocking adversaries' access to American operational technology (OT), including within domestic defense manufacturing and other U.S. critical infrastructure.

Contracts

Booz Allen Invests In Corsha To Bolster U.S. Cybersecurity In Defense And Critical Infrastructure; No Terms Disclosed

Biotech

Events

General

COCP

Cocrystal Pharma Presents Phase 1 Study Data Of First-in-Class Norovirus Protease Inhibitor CDI-988 At 9th International Calicivirus Conference

Pelthos Therapeutics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTHS#NYSE">PTHS</a>) on Thursday announced the launch of Zelsuvmi (berdazimer) topical gel 10.3% for molluscum contagiosum (molluscum) in adults and pediatric patients <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">one year of age and older</a>.
Zelsuvmi received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, and caregivers to treat molluscum infections.
Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people, most of them children, with up to 6 million new incidents per year in the United States, the company said.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44750854/analyst-sees-big-upside-in-ligands-capital-efficient-biotech-strategy" rel="noreferrer noopener">Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy</a>
Zelsuvmi is a topical nitric oxide-releasing gel for molluscum at diagnosis. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application.
It can be used to treat infections on the body, including sensitive areas such as the face, groin, or underarms.
Zelsuvmi was studied in the largest randomized clinical trial for the treatment of molluscum.
In the 891-patient phase 3 study:
<ul class="wp-block-list">
<li>Nearly 33% of patients saw complete clearance of molluscum lesions, compared with 19.7% of patients who did not receive the active ingredient at the twelfth week.</li>
<li>For many patients, Zelsuvmi demonstrated results within two weeks.</li>
</ul>
"We are launching our ZelsuvmiGo patient support program, which we expect to help onboard patients seamlessly and provide resources for caregivers," said Sai Rangarao, Chief Commercial Officer at Pelthos.
"To ensure that Zelsuvmi reaches the people who need it quickly, we have hired 50 sales territory managers across the country to work with physicians who treat a high volume of patients with molluscum."
In April, Ligand Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) and Channel Therapeutics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#NYSE">CHRO</a>) agreed to combine Ligand's wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos), with CHRO Merger Sub Inc., a wholly <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44858815/exclusive-ligand-subsidiary-pelthos-therapeutics-to-combine-with-channel-therapeutics-creating-pain-medicines-focused-entity" rel="noreferrer noopener">owned subsidiary of Channel</a>.
The merger was supported by $50 million in capital raised from a group of strategic investors led by Murchinson.
Under the merger agreement, Channel acquired 100% of Pelthos' issued and outstanding equity interests, changed its name to Pelthos Therapeutics, and started trading on the NYSE American exchange under the ticker PTHS.
Price Action: PTHS stock traded higher by 7.65% to $17.74 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asset-sales/25/07/46337777/kraft-heinz-sells-italian-infant-food-business" target="_blank" rel="noreferrer noopener">Kraft Heinz Sells Italian Infant Food Business</a></li>
</ul>
Photo via Shutterstock

Health Care

CHRO

LGND

PTHS

Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease

MBLY

Mobileye Global shares are trading lower after the company announced a secondary offering of 50 million class A shares.

BitFuFu Inc. ("BitFuFu" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>), a world-leading Bitcoin miner and mining services innovator, today reaffirmed its ongoing commitment to building a more sustainable and energy-efficient Bitcoin mining operation, highlighting key initiatives that will remain a focus through the remainder of 2025.
Thanks to strategic acquisitions and infrastructure developments made over the past nine months, BitFuFu has showcased how sustainable Bitcoin mining can scale effectively—by harnessing renewable energy resources specific to certain locations, collaborating with countries that offer abundant power capacity, and improving miner energy efficiency through advanced software technology.
BitFuFu currently aims to own 1 GW of secured power by the end of 2026 through acquisitions and greenfield developments. The shift toward owning and operating low-cost facilities supports improved cost control, scalability, and operational efficiency in a post-halving environment—thereby reducing Bitcoin mining's energy footprint.&nbsp; &nbsp;

FUFU

BitFuFu Reaffirms Commitment To Sustainable And Energy-Efficient Bitcoin Mining Operation In 2025; Currently Aims To Own 1 GW Of Secured Power By 2026 End Through Acquisitions And Greenfield Developments

ABOS

Acumen Pharmaceuticals To Present At Alzheimer's Association International Conference Jul. 28 And 29

BMO Capital analyst Daniel Jester initiates coverage on Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) with a Market Perform rating and announces Price Target of $340.

BMO Capital Initiates Coverage On Automatic Data Processing with Market Perform Rating, Announces Price Target of $340

Stephens &amp; Co. analyst Sudan Loganathan reiterates Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) with a Overweight and maintains $30 price target.

Reiteration

NRIX

Stephens & Co. Reiterates Overweight on Nurix Therapeutics, Maintains $30 Price Target

ITUB

Itau Unibanco shares are trading lower after UBS downgraded the stock from Buy to Neutral.

New Rate Reflects Expected Lower Net Interest Margins on New Investments and a Declining SOFR Curve

Dividends

SEVN

Seven Hills Realty Trust Reduces Quarterly Distribution From $0.35 To $0.28 Per Share

BMO Capital analyst Daniel Jester initiates coverage on Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) with a Market Perform rating and announces Price Target of $160.

PAYX

BMO Capital Initiates Coverage On Paychex with Market Perform Rating, Announces Price Target of $160

Press Releases

Shineco Announces New Distribution Agreements for over $30 Million in Sales for its New Health Food Beverage

Shineco Announces Proposed Underwritten Public Offering

Shineco Announces Pricing of $2 Million Underwritten Public Offering

Shineco Announces Closing of $2 Million Underwritten Public Offering

Fintech

Future FinTech Announces the Appointment of Hu Li as the New CEO

Shineco Announces Reverse Split to Regain NASDAQ Compliance

Shineco Announces Acquisition of Medical Device Company

Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company

Shineco's Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare Market

Management Confidence: Shineco Executives Launch up to $2M Open-Market Stock Purchase Program

Comments

Shineco

Shineco (SISI) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL